OM1, A healthcare data and analysis company, Raised $85 million In a Series D financing led by Oakland, California Caesars Medical Institution,and many more.
D1 Capital Partners and Breyer Capital together with Kaiser Permanente led the new round of financing, which also included the participation of existing investors such as General Catalyst, Polaris Partners, and 7wire Ventures.
The CEO of the Boston-based company, Dr. Richard Gliklich, said in an email that OM1 works with providers, medical associations, payers and manufacturers to create a data network. These networks automatically collect data from various systems (such as electronic medical records and laboratories) and patients. This data is then used to help develop or evaluate medical products and treatments. It can also be used to create artificial intelligence models that support clinical decision-making.
Gliklich said: “Clinical-real world-health data is very important when trying to evaluate patient outcomes, understand the patient’s treatment or disease journey, understand which treatment is suitable for which patients and when… etc.,” “But healthcare data is very important.” Complex, it also comes from many different systems, which need to be de-identified to protect the privacy of patients. We organize health care data so that it can be used to improve health outcomes.”
For example, clinicians can use company-provided data and tools to predict the likelihood of adverse events in knee replacement patients and determine their treatment course accordingly, Gliklich said. Similarly, pharmaceutical companies can use this data to explore how their treatments work in different patient groups and subtypes.
With new funding, OM1 will focus on expanding its real-world data network, especially in the field of chronic diseases, including dermatology, gastroenterology, rheumatology, and behavioral health. The company also plans to expand its analysis model and platform.
The company was founded in 2015 and raised a total of US$176 million.
Although the company operates in a similar way to clinical research organizations such as Covance, Medidata, and Oracle, it is not one.
Gliklich said: “The real-world clinical data market is divided into large aggregators one inch deep and one mile wide and traditional patient registration companies that focus on smaller patient populations that are individually registered and tracked by doctors.” “OM1 is working on it. Create a middle tier between these types of companies.”
In addition, Gliklich said, OM1’s AI platform applies advanced analytics and predictive modeling to clinical data, enabling it to identify patients, predict results, and encourage sharing of decisions between providers and patients.
Photo: Abscent84, Getty Images
